SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008
More News related to SUPG
- SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme
- SuperGen (SUPG) Misses Q2 View By 2c
- SuperGen Reports 2008 Second Quarter Financial Results
- SuperGen To Present at BMO Capital Markets Focus on Healthcare Conference on August 5, 2008
- SuperGen to Announce 2008 Second Quarter Financial Results August 4, 2008
More News related to Press Releases
- Books-A-Million Helps Teachers Stretch Classroom Budgets with Educators' Day
- Verizon Gets Ready for Hanna's Trip Up the East Coast
- Orthofix International Announces Expansion of Product Offerings
- Harris Corporation CEO Howard L. Lance to Speak at the Morgan Stanley Global Industrials CEO's Unplugged Conference
- A.M. Best Company to Discuss Bank Ratings at OBL/ILFI Annual Convention
DUBLIN, Calif., July 2 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the Collins Stewart Growth Conference on Wednesday, July 9, 2008 at the Mandarin Oriental Hotel in New York City.
SuperGen's presentation at the Collins Stewart Growth Conference is scheduled to begin at 4:00 p.m. EDT (1:00 p.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at www.supergen.com. A webcast replay of the presentation will be available shortly following the live event.
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
Contacts
Timothy L. Enns Mary M. Vegh
SuperGen, Inc. SuperGen, Inc.
SVP, Corporate Communications & Business Manager, Investor
Development Relations
Tel: (925) 560-0100 Tel: (925) 560-2845
E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com
SOURCE SuperGen, Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
